Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03277248 · ClinicalTrials.gov registry record · Phase 3
Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS)
A Phase 3 study of Relapsing Multiple Sclerosis (RMS), sponsored by TG Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 545
- Enrollment target
- 13
- Study locations
NCT03277248 is a Phase 3 study of Relapsing Multiple Sclerosis (RMS) that has completed, run by TG Therapeutics. The registered enrollment target is 545 participants, below the 615-participant average among 3 other Relapsing Multiple Sclerosis (RMS) trials with a reported enrollment target (11% lower). The trial reports 13 study locations across 13 states.
The verdict
NCT03277248, a Phase 3 study of Relapsing Multiple Sclerosis (RMS), has completed, sponsored by TG Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 545 participants
- Enrollment target
- 13
- Study locations
Study Summary
This study determines the Annualized Relapse Rate (ARR) in participants with RMS after 96 weeks (approximately 2 years) treatment with intravenous (IV) infusion of ublituximab/oral placebo compared to 14 mg oral teriflunomide/IV placebo.
Conditions Studied
Interventions
- BIOLOGICAL Ublituximab
- DRUG Oral Placebo
- DRUG Teriflunomide
- DRUG IV Placebo
Study Locations (13)
Arizona
- TG Therapeutics RMS Investigational Trial site - Phoenix
Colorado
- TG Therapeutics RMS Investigational Trial Site - Aurora
Florida
- TG Therapeutics RMS Investigational Trial Site - Tampa
Kentucky
- TG Therapeutics RMS Investigational Trial Site - Lexington
Missouri
- TG Therapeutics RMS Investigational Trial Site - Chesterfield
Nevada
- TG Therapeutics RMS Investigational Trial Site - Las Vegas
New Jersey
- TG Therapeutics RMS Investigational Trial Site - Teaneck
New Mexico
- TG Therapeutics RMS Investigational Trial Site - Albuquerque
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 545 participants |
| Start Date | 2017-08-25 |
| Est. Completion | 2020-11-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03277248
The ClinicalTrials.gov registry entry for NCT03277248 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 545 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 615-participant average among 3 other Relapsing Multiple Sclerosis (RMS) trials with a reported enrollment target (11% lower). The listed sponsor is TG Therapeutics, which has 33 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Relapsing Multiple Sclerosis (RMS) appearing as the primary indexed condition, and to 4 interventions - of which Ublituximab is the first listed.
NCT03277248 reports 13 study locations spanning 13 distinct geographic areas - top geographies include Arizona, Colorado, Florida.
Frequently Asked Questions
What is clinical trial NCT03277248 about?
NCT03277248 is a clinical study titled "Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS)". This study determines the Annualized Relapse Rate (ARR) in participants with RMS after 96 weeks (approximately 2 years) treatment with intravenous (IV) infusion of ublituximab/oral placebo compared to 14 mg oral teriflunomide/IV placebo.
What is the current status of trial NCT03277248?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 545 participants. The study started on 2017-08-25. Estimated completion is 2020-11-12.
What conditions does trial NCT03277248 study?
This clinical trial studies the following conditions: Relapsing Multiple Sclerosis (RMS).
What interventions are being tested in trial NCT03277248?
The interventions under investigation include: Ublituximab (BIOLOGICAL), Oral Placebo (DRUG), Teriflunomide (DRUG), IV Placebo (DRUG).
Who is sponsoring clinical trial NCT03277248?
This trial is sponsored by TG Therapeutics, which has 33 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03277248 being conducted?
This trial has 13 study locations across Arizona, Colorado, Florida, Kentucky, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Relapsing Multiple Sclerosis (RMS)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a New Maintenance Dosing Regimen of Ofatumumab
ACTIVE NOT RECRUITING · Phase 3
-
An Extension Study of Ublituximab in Participants With Relapsing Multiple Sclerosis
ACTIVE NOT RECRUITING · Phase 3
-
Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS) ( ULTIMATE 1 )
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.